{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-035508","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.599269+00:00","generated_at":"2026-05-16T05:28:30.598594+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Perspective Therapeutics prices $175M offering of common stock and pre-funded warrants at $3.79/share","bullets":["Gross proceeds ~$175M from 39,576,088 shares at $3.79/share and 6,598,046 pre-funded warrants at $3.789.","Offering closed Feb 3, 2026; net proceeds to fund clinical development, manufacturing, and general corp purposes.","Underwriters include Piper Sandler, UBS, Oppenheimer, Truist, and LifeSci Capital.","Participation from Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital (Citadel), and others."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-035508","json":"https://secwatch.observer/filing/0001193125-26-035508.json","markdown":"https://secwatch.observer/filing/0001193125-26-035508.md","text":"https://secwatch.observer/filing/0001193125-26-035508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526035508/0001193125-26-035508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526035508/catx-20260202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:28:30.598594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d8cf02ad219868c679680f9331e2c77e6fca004","claim":"Perspective Therapeutics, Inc. entered into Underwriting Agreement with Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein valued at approximately $175 million (effective 2026-02-02).","evidence_excerpt":"On February 2, 2026, Perspective Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten offering (the “Offering”) of 39,576,088 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and, in lieu of Shares to certain investors, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 6,598,046 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000119312526035508/0001193125-26-035508-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein"},{"label":"Value","value":"approximately $175 million"},{"label":"Effective","value":"2026-02-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}